Home/Filings/4/0001104659-18-043797
4//SEC Filing

Cavan John T 4

Accession 0001104659-18-043797

CIK 0001583771other

Filed

Jul 2, 8:00 PM ET

Accepted

Jul 3, 2:17 PM ET

Size

7.8 KB

Accession

0001104659-18-043797

Insider Transaction Report

Form 4
Period: 2018-07-03
Cavan John T
Chief Financial Officer
Transactions
  • Purchase

    Series C Convertible Preferred Stock

    2018-07-03$1000.00/sh+15$15,00015 total
    Exercise: $1.55From: 2018-07-03Common Stock (9,678 underlying)
  • Purchase

    Warrants

    2018-07-03$1000.00/sh+8,625$8,625,0008,625 total
    Exercise: $1.55From: 2018-07-03Exp: 2023-07-03Common Stock (8,625 underlying)
Footnotes (3)
  • [F1]Each share of Series C Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $1.55.
  • [F2]Shares of Series C Convertible Preferred Stock do not expire.
  • [F3]Shares of Series C Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series C Convertible Preferred Stock and 575 Warrants

Documents

1 file

Issuer

ContraVir Pharmaceuticals, Inc.

CIK 0001583771

Entity typeother

Related Parties

1
  • filerCIK 0001503738

Filing Metadata

Form type
4
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 2:17 PM ET
Size
7.8 KB